Preview

Problems of Endocrinology

Advanced search

Screening for gestational diabetes due to of the COVID-19 pandemic

https://doi.org/10.14341/probl12482

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus that causes coronavirus disease in 2019 (COVID-19). Currently, there is no evidence that pregnant women are more vulnerable to COVID-19. All concerns and anticipated risks are related to the potential impact of COVID-19 on perinatal outcomes, so pregnant women require special attention in relation to the preventive measures, diagnosis and treatment of a new coronavirus disease. Women with gestational diabetes mellitus (GDM) belong to the group of high perinatal risk and need timely medical assistance. During the COVID-19 pandemic, there is a necessity in temporary changes of approaches to diagnosing GSD and pregnancy care before and after delivery in women with GSD. The purpose of our review is to present and analyze all available GSD screening recommendations, updated and published in various countries in response to the coronavirus pandemic, at the time of publication of this article. It seems that there is no single universal strategy to achieve a reasonable balance. In this regard, it is necessary to develop new national algorithms for GSD screening, taking into account both demographic factors and the features and capabilities of our health system. We believe that the knowledge and experience achieved as a result of these changes will lead to the revision and improvement of national and international recommendations.

About the Authors

Ayarpi O. Torosyan
RUDN University
Russian Federation

postgraduate



Ekaterina V. Loginova
RUDN University
Russian Federation

postgraduate



Chelebi G. Gagaev
RUDN University
Russian Federation

MD, PhD, Professor



References

1. Poon L, Yang Н, Kapur A, et al. Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals. Int J Gynaecol Obstet. 2020;149(3):273−286. doi: 10.1002/ijgo.13156.

2. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak − an update on the status. Mil Med Res. 2020;7(1):11. doi: 10.1186/s40779-020-00240-0.

3. Gorbalenya AE, Baker SC, Baric RS, et al; Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–544. doi: 10.1038/s41564-020-0695-z.

4. acog.org [Internet]. The American College of Obstetricians and Gynecologists [cited 2020 May 19]. Available from: https://www.acog.org/search#q=The%20American%20College%20of%20Obstetricians%20and%20Gynecologists%20&sort=relevancy.

5. Coronavirus (COVID-19) Infection in Pregnancy. Version 10. RCOG [cited 2020 July 24]. Available from: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/coronavirus-pregnancy/.

6. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020. doi: 10.1001/jama.2020.2648.

7. Khan S, Jun L, Nawsherwan, et al. Association of COVID-19 with pregnancy outcomes in health-care workers and general women. Clin Microbiol Infect. 2020;26(6):788−790. doi: 10.1016/j.cmi.2020.03.034.

8. Qiancheng X, Jian S, Lingling P, et al. Coronavirus disease 2019 in pregnancy. Int J Infect Dis. 2020;95:376−383. doi: 10.1016/j.ijid.2020.04.065.

9. Yang H, Sun G, Tang F, et al. Clinical features and outcomes of pregnant women suspected of coronavirus disease 2019. J Infect. 2020;81(1):e40−e44 doi: 10.1016/j.jinf.2020.04.003.

10. Chen L, Li Q, Zheng D, et al. Clinical characteristics of pregnant women with Covid-19 in Wuhan, China. N Engl J Med. 2020;382(25):e100. doi: 10.1056/NEJMc2009226.

11. Elshafeey F, Magdi R, Hindi N, et al. A systematic scoping review of COVID-19 during pregnancy and childbirth. Int J Gynaecol Obstet. 2020;150(1):47−52. doi: 10.1002/ijgo.13182.

12. Karami P, Naghavi M, Feyzi A, et al. WITHDRAWN: Mortality of a pregnant patient diagnosed with COVID-19: A case report with clinical, radiological, and histopathological findings. Travel Med Infect Dis. 2020;101665. doi: 10.1016/j.tmaid.2020.101665.

13. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, et al. Maternal death due to COVID-19. Am J Obstet Gynecol. 2020;223(1):109.e1−109.e16. doi: 10.1016/j.ajog.2020.04.030.

14. Ahmed I, Azhar A, Eltaweel N, Tan BK. First COVID-19 maternal mortality in the UK associated with thrombotic complications. Br J Haematol. 2020;190(1):e37−e38. doi: 10.1111/bjh.16849.

15. Kirtsman M, Diambomba Y, Poutanen SM, et al. Probable congenital SARS-CoV-2 infection in a neonate born to a woman with active SARS-CoV-2 infection. CMAJ. 2020;192(24):E647−E650. doi: 10.1503/cmaj.200821.

16. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91−95. doi: 10.1016/j.ijid.2020.03.017.

17. Boelig RC, Saccone G, Bellussi F, Berghella V. MFM Guidance for COVID-19. Am J Obstet Gynecol MFM. 2020;2(2):100106. doi: 10.1016/j.ajogmf.2020.100106.

18. Shakila T, Cooray SD, Nithya S, et al. Endocrinology in the time of COVID-19: diagnosis and management of gestational diabetes mellitus. Eur J Endocrinol. 2020;183(2):G49−G56. doi: 10.1530/EJE-20-0401.

19. Kasuga Y, Saisho Y, Ikenoue S, et al. A new diagnostic strategy for gestational diabetes during the COVID-19 pandemic for the Japanese population. Diabetes Metab Res Rev. 2020;e3351. doi: 10.1002/dmrr.3351.

20. The Australasian Diabetes in Pregnancy Society (ADIPS), the Australian Diabetes Society (ADS), the Australian Diabetes Educators Association (ADEA) and Diabetes Australia (DA). Diagnostic testing for gestational diabetes mellitus (GDM) during the COVID-19 pandemic: Antenatal and postnatal testing advice. Queensland Clinical Guidelines. 2020. Available from: https://www.adips.org/documents/COVID19-WITHQLDGUIDELINES0704201150ADIPSADSADEADAupdated_000.pdf.

21. McIntyre HD, Moses RG. The Diagnosis and management of gestational diabetes mellitus in the context of the COVID-19 Pandemic. Diabetes Care. 2020;43(7):1433−1434. doi: 10.2337/dci20-0026.

22. Рекомендации по организации работы по профилактике новой коронавирусной инфекции (COVID-19) при оказании медицинской помощи по профилю «акушерство и гинекология» Департамента здравоохранения города Москвы № 01-301/20 от 02.04.2020. [Rekomendatsii po organizatsii raboty po profilaktike novoy koronavirusnoy infektsii (COVID-19) pri okazanii meditsinskoy pomoshchi po profilyu «akusherstvo i ginekologiya» Departamenta zdravookhraneniya goroda Moskvy N 01-301/20, dated 2 April 2020. (In Russ).]

23. Vambergue A, Jacqueminet S, Lamotte MF, et al. Three alternative ways to screen for hyperglycaemia in pregnancy during the COVID-19 pandemic. Diabetes and Metabolism. 2020;S1262-3636(20)30059-8. doi: 10.1016/j.diabet.2020.04.003.

24. Queensland Clinical Guideline: Gestational Diabetes for changes to screening and diagnosis of GDM during COVID-19 pandemic. 2020. Available from: https://www.health.qld.gov.au/__data/assets/pdf_file/0022/950503/g-gdm.pdf.

25. Thangaratinam S, Saravanan P, Huda MS, et al. Guidance for maternal medicine in the evolving coronavirus Covid-19 pandemic [cited 2020 May 6]. Available from: www.rcog.org.uk/globalassets/documents/https://www.rcog.org.uk/globalassets/documents/guidelines/2020-07-10-guidance-for-maternal-medicine.pdf

26. Cosson E, Vicaut E, Sandre-Banon D, et al. Performance of a selective screening strategy for diagnosis of hyperglycaemia in pregnancy as defined by IADPSG/WHO criteria. Diabetes and Metabolism. 2019;S1262-3636(19)30157-0. doi: 10.1016/j.diabet.2019.09.002.

27. Yamamoto YD, Donovan LE, Feig DS, Berger HB. Urgent update – temporary alternative screening strategy for gestational diabetes screening during the COVID-19 pandemic: a joint consensus statement from the Diabetes Canada Clinical Practice Guidelines Steering Committee and the Society of Obstetricians and Gynaecologists of Canada. Available from: https://www.sogc.org/common/Uploaded%20files/GDM-COVID-19%20temporary%20screening%20guidelines%20-%2020200402%20Agreed%20Final.pdf.

28. Metzger BE, Lowe LP, Dyer AR, et al.; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991−2002. doi: 10.1056/NEJMoa0707943.

29. Lowe LP, Metzger BE, Dyer AR, et al.; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcome (HAPO) study: associations of maternal A1C and glucose with pregnancy outcomes. Diabetes Care. 2012;35(3):574–580. doi: 10.2337/dc11-1687.

30. Ye M, Liu Y, Cao X, et al. The utility of HbA1c for screening gestational diabetes mellitus and its relationship with adverse pregnancy outcomes. Diabetes Res Clin Pract. 2016;114:43−49. doi: 10.1016/j.diabres.2016.02.007.


Supplementary files

Review

For citations:


Torosyan A.O., Loginova E.V., Gagaev Ch.G. Screening for gestational diabetes due to of the COVID-19 pandemic. Problems of Endocrinology. 2020;66(3):56-61. (In Russ.) https://doi.org/10.14341/probl12482

Views: 5700


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)